Patient details
| . | Infection cohort . | |||
|---|---|---|---|---|
| Characteristics . | AdV (n = 18) . | CMV (n = 23) . | EBV (n = 9) . | Total (n = 50) . |
| Sex (n, %) | ||||
| Male | 12 (66.7) | 17 (73.9) | 4 (44.4) | 33 (66.0) |
| Ethnicity (n, %) | ||||
| Hispanic or Latino | 6 (33.3) | 4 (17.4) | 2 (22.2) | 12 (24.0) |
| Race (n, %) | ||||
| Black or African American | 3 (16.7) | 4 (17.4) | 0 (0.0) | 7 (14.0) |
| White | 13 (72.2) | 16 (69.6) | 9 (100.0) | 38 (76.0) |
| Age at infusion (y) | ||||
| Mean (SD) | 18.0 (17.5) | 36.6 (25.6) | 34.5 (17.9) | 29.5 (23.0) |
| Transplant type (n, %) | ||||
| Bone marrow | 8 (44.4) | 5 (21.7) | 1 (11.1) | 14 (28.0) |
| Peripheral blood stem cell | 5 (27.8) | 14 (60.9) | 2 (22.2) | 21 (42.0) |
| Single cord blood | 3 (16.7) | 2 (8.7) | 0 (0.0) | 5 (10.0) |
| Double cord blood | 2 (11.1) | 2 (8.7) | 6 (66.7) | 10 (20.0) |
| HLA match (recipient to first VST line) (n, %)* | ||||
| 1/6 | 5 (27.8) | 4 (17.4) | 3 (33.3) | 12 (24.0) |
| 2/6 | 9 (50.0) | 12 (52.2) | 3 (33.3) | 24 (48.0) |
| 3/6 | 3 (16.7) | 6 (26.1) | 3 (33.3) | 12 (24.0) |
| 4/6 | 1 (5.6) | 1 (4.3) | 0 (0.0) | 2 (4.0) |
| Number of infusions (n, %) | ||||
| 1 | 15 (83.3) | 17 (73.9) | 4 (44.4) | 36 (72.0) |
| 2 | 2 (11.1) | 4 (17.4) | 1 (11.1) | 7 (14.0) |
| 3 | 1 (5.6) | 2 (8.7) | 3 (33.3) | 6 (12.0) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 6 | 0 (0.0) | 0 (0.0) | 1 (11.1) | 1 (2.0) |
| . | Infection cohort . | |||
|---|---|---|---|---|
| Characteristics . | AdV (n = 18) . | CMV (n = 23) . | EBV (n = 9) . | Total (n = 50) . |
| Sex (n, %) | ||||
| Male | 12 (66.7) | 17 (73.9) | 4 (44.4) | 33 (66.0) |
| Ethnicity (n, %) | ||||
| Hispanic or Latino | 6 (33.3) | 4 (17.4) | 2 (22.2) | 12 (24.0) |
| Race (n, %) | ||||
| Black or African American | 3 (16.7) | 4 (17.4) | 0 (0.0) | 7 (14.0) |
| White | 13 (72.2) | 16 (69.6) | 9 (100.0) | 38 (76.0) |
| Age at infusion (y) | ||||
| Mean (SD) | 18.0 (17.5) | 36.6 (25.6) | 34.5 (17.9) | 29.5 (23.0) |
| Transplant type (n, %) | ||||
| Bone marrow | 8 (44.4) | 5 (21.7) | 1 (11.1) | 14 (28.0) |
| Peripheral blood stem cell | 5 (27.8) | 14 (60.9) | 2 (22.2) | 21 (42.0) |
| Single cord blood | 3 (16.7) | 2 (8.7) | 0 (0.0) | 5 (10.0) |
| Double cord blood | 2 (11.1) | 2 (8.7) | 6 (66.7) | 10 (20.0) |
| HLA match (recipient to first VST line) (n, %)* | ||||
| 1/6 | 5 (27.8) | 4 (17.4) | 3 (33.3) | 12 (24.0) |
| 2/6 | 9 (50.0) | 12 (52.2) | 3 (33.3) | 24 (48.0) |
| 3/6 | 3 (16.7) | 6 (26.1) | 3 (33.3) | 12 (24.0) |
| 4/6 | 1 (5.6) | 1 (4.3) | 0 (0.0) | 2 (4.0) |
| Number of infusions (n, %) | ||||
| 1 | 15 (83.3) | 17 (73.9) | 4 (44.4) | 36 (72.0) |
| 2 | 2 (11.1) | 4 (17.4) | 1 (11.1) | 7 (14.0) |
| 3 | 1 (5.6) | 2 (8.7) | 3 (33.3) | 6 (12.0) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 6 | 0 (0.0) | 0 (0.0) | 1 (11.1) | 1 (2.0) |
Patients were accrued and treated at Baylor College of Medicine (n = 18, of which 14 were enrolled at Texas Children’s Hospital and 4 at The Methodist Hospital), MD Anderson Cancer Center (n = 14), Duke University (n = 8), Dana-Farber Cancer Center (n = 4), Children’s Hospital of Los Angeles (n = 3), Hackensack University Medical Center (n = 2), and Massachusetts General Hospital (n = 1).
Matching by low-resolution typing.28